Academic Bibliography

 Search 200 years of publications by Ghent University researchers.
Advanced search
Add to list
  1. Search results
  2. Risk of malignancies in patients with...

Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies

F Beigel, A Steinborn, F Schnitzler, C Tillack, S Breiteneicher, JM John, Kristel Van Steen (UGent) , RP Laubender, B Goke, J Seiderer, et al.
(2014) PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. 23(7). p.735-744
Author
Organization
Abstract
Purpose We aimed to analyse malignancy rates and predictors for the development of malignancies in a large German inflammatory bowel disease (IBD) cohort treated with thiopurines and/or anti-tumour necrosis factor (TNF) antibodies. Methods De novo malignancies in 666 thiopurine-treated and/or anti-TNF-treated IBD patients were analysed. Patients (n = 262) were treated with thiopurines alone and never exposed to anti-TNF antibodies (TP group). In addition, patients (n = 404) were exposed to anti-TNF antibodies (TNF+ group) with no (7.4%), discontinued (80.4%) or continued (12.1%) thiopurine therapy. Results In the TP group, 20 malignancies were observed in 18 patients compared with 8 malignancies in 7 patients in the TNF+ group (hazard ratio 4.15; 95% CI 1.82-9.44; p = 0.0007; univariate Cox regression). Moreover, 18.2% of all patients in the TP group >= 50 years of age developed a malignancy, compared with 3.8% of all patients <50 years of age (p = 0.0008). In the TNF+ group, 6.5% of all patients >= 50 years of age developed malignancies compared with 0.3% of all patients < 50 years of age (p = 0.0007). In both groups combined, thiopurine treatment duration >= 4 years was associated with the risk for skin cancer (p = 0.0024) and lymphoma (p = 0.0005). Conclusions Our data demonstrate an increased risk for the development of malignancies in IBD patients treated with thiopurines in comparison with patients treated with anti-TNF antibodies with or without thiopurines. Copyright (C) 2014 John Wiley & Sons, Ltd.
Keywords
AZATHIOPRINE, INFLIXIMAB, SAFETY, INFECTIONS, inflammatory bowel disease, infliximab, adalimumab, thiopurines, anti-TNF antibodies, malignancy, pharmacoepidemiology, lymphoma, skin cancer, azathioprine, cancer, carcinoma, melanoma, tumor, NONMELANOMA SKIN CANCERS, T-CELL LYMPHOMA, CROHNS-DISEASE, RHEUMATOID-ARTHRITIS, INFLIXIMAB, AZATHIOPRINE, SAFETY, INDUCTION, THERAPY, INFECTIONS

Citation

Please use this url to cite or link to this publication:

MLA
Beigel, F., et al. “Risk of Malignancies in Patients with Inflammatory Bowel Disease Treated with Thiopurines or Anti-TNF Alpha Antibodies.” PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, vol. 23, no. 7, WILEY-BLACKWELL, 2014, pp. 735–44, doi:10.1002/pds.3621.
APA
Beigel, F., Steinborn, A., Schnitzler, F., Tillack, C., Breiteneicher, S., John, J., … Ochsenkuhn, T. (2014). Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 23(7), 735–744. https://doi.org/10.1002/pds.3621
Chicago author-date
Beigel, F, A Steinborn, F Schnitzler, C Tillack, S Breiteneicher, JM John, Kristel Van Steen, et al. 2014. “Risk of Malignancies in Patients with Inflammatory Bowel Disease Treated with Thiopurines or Anti-TNF Alpha Antibodies.” PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 23 (7): 735–44. https://doi.org/10.1002/pds.3621.
Chicago author-date (all authors)
Beigel, F, A Steinborn, F Schnitzler, C Tillack, S Breiteneicher, JM John, Kristel Van Steen, RP Laubender, B Goke, J Seiderer, S Brand, and T Ochsenkuhn. 2014. “Risk of Malignancies in Patients with Inflammatory Bowel Disease Treated with Thiopurines or Anti-TNF Alpha Antibodies.” PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 23 (7): 735–744. doi:10.1002/pds.3621.
Vancouver
1.
Beigel F, Steinborn A, Schnitzler F, Tillack C, Breiteneicher S, John J, et al. Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. 2014;23(7):735–44.
IEEE
[1]
F. Beigel et al., “Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies,” PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, vol. 23, no. 7, pp. 735–744, 2014.
@article{5906283,
  abstract     = {Purpose We aimed to analyse malignancy rates and predictors for the development of malignancies in a large German inflammatory bowel disease (IBD) cohort treated with thiopurines and/or anti-tumour necrosis factor (TNF) antibodies. Methods De novo malignancies in 666 thiopurine-treated and/or anti-TNF-treated IBD patients were analysed. Patients (n = 262) were treated with thiopurines alone and never exposed to anti-TNF antibodies (TP group). In addition, patients (n = 404) were exposed to anti-TNF antibodies (TNF+ group) with no (7.4%), discontinued (80.4%) or continued (12.1%) thiopurine therapy. Results In the TP group, 20 malignancies were observed in 18 patients compared with 8 malignancies in 7 patients in the TNF+ group (hazard ratio 4.15; 95% CI 1.82-9.44; p = 0.0007; univariate Cox regression). Moreover, 18.2% of all patients in the TP group >= 50 years of age developed a malignancy, compared with 3.8% of all patients <50 years of age (p = 0.0008). In the TNF+ group, 6.5% of all patients >= 50 years of age developed malignancies compared with 0.3% of all patients < 50 years of age (p = 0.0007). In both groups combined, thiopurine treatment duration >= 4 years was associated with the risk for skin cancer (p = 0.0024) and lymphoma (p = 0.0005). Conclusions Our data demonstrate an increased risk for the development of malignancies in IBD patients treated with thiopurines in comparison with patients treated with anti-TNF antibodies with or without thiopurines. Copyright (C) 2014 John Wiley & Sons, Ltd.},
  author       = {Beigel, F and Steinborn, A and Schnitzler, F and Tillack, C and Breiteneicher, S and John, JM and Van Steen, Kristel and Laubender, RP and Goke, B and Seiderer, J and Brand, S and Ochsenkuhn, T},
  issn         = {1053-8569},
  journal      = {PHARMACOEPIDEMIOLOGY AND DRUG SAFETY},
  keywords     = {AZATHIOPRINE,INFLIXIMAB,SAFETY,INFECTIONS,inflammatory bowel disease,infliximab,adalimumab,thiopurines,anti-TNF antibodies,malignancy,pharmacoepidemiology,lymphoma,skin cancer,azathioprine,cancer,carcinoma,melanoma,tumor,NONMELANOMA SKIN CANCERS,T-CELL LYMPHOMA,CROHNS-DISEASE,RHEUMATOID-ARTHRITIS,INFLIXIMAB,AZATHIOPRINE,SAFETY,INDUCTION,THERAPY,INFECTIONS},
  language     = {eng},
  number       = {7},
  pages        = {735--744},
  publisher    = {WILEY-BLACKWELL},
  title        = {Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies},
  url          = {http://dx.doi.org/10.1002/pds.3621},
  volume       = {23},
  year         = {2014},
}
Altmetric
View in Altmetric
Web of Science
Times cited: